Association between diarrhea and quality of life in HIV-infected patients receiving highly active antiretroviral therapy

Quality of Life Research

Volumn 13, Issue 1, 2004, Pages 243-250

  Tramarin, Andrea ^a,n   Parise, Nicoletta ^a   Campostrini, Stefano ^a   Yin, Donald D ^b   Postma, Maarten J ^c   Lyu, Ramon ^d   Grisetti, Roberta ^e   Capetti, Amedeo ^e   Cattelan, Anna Maria ^f   Di Toro, Maria Teresa ^g   Mastroianni, Antonio ^h   Pignattari, Elena ⁱ   Mondardini, Valeria ^j   Calleri, Guido ^k   Raise, Enzo ^l   Starace, Fabrizio ^m  

^a UNIVERSITY OF PADOVA   (Italy)

^b MERCK RESEARCH LABORATORIES   (United States)

^c UNIVERSITY OF GRONINGEN   (Netherlands)

^d RUTGERS UNIVERSITY   (United States)

^e UNIVERSITY OF MILAN   (Italy)

^f Ospedale Civile   (Italy)

^g Ospedale San Giovanni di Dio   (Italy)

^h Osp M   (Italy)

ⁱ UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^j SAN MARTINO HOSPITAL   (Italy)

^k AMEDEO DI SAVOIA HOSPITAL   (Italy)

^l Ospedale SS Giovanni e Paolo   (Italy)

^m AO Dei Colli Hospital for Infectious Diseases D Cotugno   (Italy)

ⁿ Ospedale Civile San Bortolo   (Italy)

more..

Author keywords

AIDS; Diarrhea; Highly active antiretroviral therapy (HAART); HIV; MOS HIV; Quality of life

Indexed keywords

ANTIVIRUS AGENT; CD4 ANTIGEN; INDINAVIR; WATER;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; ASSOCIATION; CELL COUNT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; FEMALE; HEALTH STATUS; HEALTH SURVEY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTESTINE MOTILITY; ITALY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE REGRESSION; OUTPATIENT DEPARTMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; STUDENT T TEST;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CASE-CONTROL STUDIES; DIARRHEA; FEMALE; HIV INFECTIONS; HUMANS; ITALY; MALE; MIDDLE AGED; QUALITY OF LIFE; REGRESSION ANALYSIS; SICKNESS IMPACT PROFILE;

EID: 12144288062     PISSN: 09629343     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:QURE.0000015282.24774.36     Document Type: Article

References (25)

1. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Panel on Clinical Practices for Treatment of HIV Infection convened by the Department of Health and Human Services (DHHS) and the Henry J. Kaiser Family Foundation. April 23, 2001. http:// www.hivatis.org/guidelines/ adult/Apr23_01/pdf/ AAAPR 23S. PDF.
2. Carpenter CC, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1997. JAMA 1997; 227: 1962-1969.
3. Carpenter CC, Cooker DA, Fischl MA, et al. Antiretroviral therapy in adults: Updated recommendations of the International AIDS Society-USA Panel. JAMA 2000; 283: 381-390.
4. Sherman DS, Fish DN. Management of protease inhibitor-associated diarrhea. Clin Infect Dis 2000; 30: 908-914.
5. El Serag HB, Olden K, Bjorkman D. Health-related quality of life among persons with irritable bowel syndrome: A systematic review. Aliment Pharmacol Ther 2002; 16(6): 1171-1185.
6. Snijders F, de Boer JB, Steenbergen B, Schouten M, Danner SA, van Dam FS. Impact of diarrhea and fecal incontinence on the daily life of HIV-infected patients. AIDS Care 1998; 10: 629-637.
7. Watson A, Samore MH, Wanke CA. Diarrhea and quality of life in ambulatory HIV-infected patients. Dig Dis Sci 1996; 41: 1794-1800.
8. Tramarin A, Alessi F, Calleri G, De Lalla F. The Palladio Pharmacoeconomic Study (PPES): Preliminary results. 37th of Annual Meeting Infectious Diseases Society of America, Philadelphia, 18-21 November 1999, Abstract book page 132.
9. Wu AW, Rubin HR, Mathews WC, et al. A health status questionnaire using 30 items from the Medical Outcome Study preliminary validation in person with early HIV infection. Med Care 1991; 29: 786-798.
10. Wu AW, Revicki DA, Jacobson D, Malitz FE. Evidence for reliability, validity and usefulness of the Medical Outcome Study HIV Health Survey (MOS-HIV). Qual Life Res 1997; 29: 786-798.
11. Bucciardini R, Wu AW, Floridia M, et al. Stefano Vella for the Istituto Superiore di Sanità 047 study: Quality of life outcomes of combination zidovudine-didanosine-nevirapine and zidovudine-didanosine for antiretroviral-naive advanced HIV-infected patients. AIDS 2000; 14: 2567-2574.
12. O'Keefe EA, Talley NJ, Zinsmeister AR, Jacobsen SJ. Bowel disorders impair functional status and quality of life in the elderly population-based study. J Gerontol A Biol Sci Med Sci 1995; 50(4): 84-89.
13. Cunningham WE, Shapiro MF, Hays RD, et al. Constitutional symptoms and health-related quality of life in patients with symptomatic HIV disease. Am J Med 1998; 104: 129-136.
14. Lubeck DP, Bennett CL, Mazonson PD, Fifer SK, Fries JF. Quality of life and health service use among HIV-infected patients with chronic diarrhea. J Acquir Immune Defic Syndr 1993; 6: 478-484.
15. Wachtel T, Piette J, Mor V, Stein M, Fleishman J, Carpenter C. Quality of life in persons with human immunodeficiency virus infection: Measurement by the Medical Outcomes Study Instrument. Ann Intern Med 1992; 116(2): 129-137.
16. Hays RD, Cunningham WE, Sherbourne CD, et al. Health-related quality of life in patients with human immunodeficiency virus infection in the United States: Results from the HIV Cost and Services Utilization Study. Am J Med 2000; 108(9): 714-722.
17. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338: 853-860.
18. Mocroft A, Vella S, Benfield TL, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet 1998; 352: 1725-1730.
19. Vittinghoff E, Scheer S, O'Malley P, et al. Combination antiretroviral therapy and recent declines in AIDS incidence and mortality. J Infect Dis 1999; 179: 717-720.
20. Mouton Y, Alfandari S, Valette M, et al. Impact of protease inhibitors on AIDS-defining events and hospitalisations in 10 French AIDS reference centres. AIDS 1997; 11: F101-F105.
21. Keiser P, Kvanli MB, Turner D, et al. Protease inhibitors therapy is associated with decreased HIV related health care costs in men treated at a Veteran Administration Hospital. J Acquir Immune Defic Syndr Hum Retrovirol 1999; 20: 28-33.
22. Beck EJ, Mandalia S, Williams I, et al. Decreased morbidity and use of hospital services in English HIV-infected individuals with increased uptake of antiretroviral therapy 1996-1997. AIDS 1999; 13: 2157-2164.
23. Moore RD. Cost-effectiveness of combination HIV therapy: 3 year later. Pharmacoeconomics 2000; 17: 325-330.
24. Bos J M, de Jong-van den Berg LTW, Postma MJ. Pharmacoeconomic evaluation of intensified antiretroviral treatment strategies in HIV/AIDS. Expert Review of Pharmacoecon Outcomes Res 2001; 1: 77-84.
25. Black N. Why we need observational studies to evaluate the effectiveness of health care? Br Med J 1996; 312: 1215-1218.